Our warmest congratulations to Professor Giuseppe Di Giovanni, who has been elected Secretary-General of the World Neuroscience Organization IBRO.
IBRO (International Brain Research Organization) is the global association of neuroscience societies established in 1961 that aims to promote and support neuroscience around the world through training, education, research, outreach and engagement activities, and the publication of our two journals, Neuroscience and IBRO Neuroscience Reports.
Prof. Di Giovanni will serve as Secretary General elect in 2023 and start his term as Secretary General in 2024. Prof Di Giovanni, together with the President Tracey Bale (USA) and the Treasurer Jerome Sanes (USA), will provide leadership with the potential to make a powerful impact on global neuroscience by overseeing, promoting and guiding the IBRO organization as a whole. He will work with over 90 international, national and regional scientific member organizations, five Regional Committees, Young IBRO, Secretariat staff and other groups and like-minded partners to ensure that the needs of neuroscientists everywhere are met, global priorities are identified and gaps in knowledge, investment and resources in brain research are bridged.
"I am delighted and humbled to have been elected to the role of Secretary-General of the World Neuroscience IBRO organization", said Professor Di Giovanni. “It means a great deal that neuroscientists across the world have put their faith in me and I want nothing more than to deliver for them all.â€
Giuseppe Di Giovanni is a Professor of the Department of Physiology & Biochemistry at the Faculty of Medicine & Surgery of the University of Malta, an Honorary Professor at Cardiff University. He is the Editor-in-Chief of Journal Neuroscience Methods by Elsevier and the President of the Mediterranean Neuroscience Society. He has recently been elected member of the Academia Europaea for the section of Physiology and Neuroscience. Professor Di Giovanni is recognized for his work and expertise in biological psychiatry, such as breakthroughs in neurotransmitter (i.e., serotonin, dopamine GABA and cannabinoids) alterations in different CNS disorders.
